A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

NCT07584967 | Not Yet Recruiting Phase 2 DMC FDA Drug

• 3 other identifiers: AC01-022025-524469-25-00PIP number
• Study Type: interventional
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.

Conditions

Heart Failure With Reduced Ejection Fraction (HFrEF)

Keywords

Heart Diseases; Cardiovascular Diseases; Heart Failure

Outcome Measures

Primary Outcomes (1)

• Absolute Change from Baseline in Composite Echocardiography Z-Score at Week 12

  The composite echocardiography Z-score integrates left ventricular stroke volume (LVSV), left ventricular end systolic volume (LVESV), left ventricular ejection fraction (LVEF), and left atrial minimal volume index (LAVImin).

  Baseline and Week 12

Secondary Outcomes (21)

• Absolute Change from Baseline in LVSV at Week 12

  Baseline and Week 12

• Absolute Change from Baseline in LVEF at Week 12

  Baseline and Week 12

• Absolute Change from Baseline in LVESV at Week 12

  Baseline and Week 12

• Absolute Change From Baseline in LAVImin at Week 12

  Baseline and Week 12

• Absolute Change from Baseline in N-terminal prohormone of Brain Natriuretic Peptide (NT-proBNP)

  Baseline and Week 12

Study Arms (3)

AC01 3 mg

EXPERIMENTAL

Participants will receive AC01 orally twice daily (BID) for 12 weeks.

Drug: AC01

AC01 1 mg

EXPERIMENTAL

Participants will receive AC01 orally BID for 12 weeks.

Drug: AC01

Placebo

PLACEBO COMPARATOR

Participants will receive matching placebo orally BID for 12 weeks.

Other: Placebo

Interventions

AC01 DRUG

AC01 tablets for oral administration.

AC01 1 mg; AC01 3 mg

Placebo OTHER

AC01 matching placebo tablets for oral administration.

Placebo

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• History of Congestive Heart Failure (CHF) diagnosed greater than or equal to (\>=6) months before screening, and in NYHA Class II to IV at screening.
• Chronic advanced HFrEF defined as:
• LVEF less than or equal to (\<=) 5 percentage (%) by local reading \>=6 months before screening or a record of LVEF qualitatively described
• LVEF \<=35% at the screening echocardiography (confirmed by core lab), and
• No known LVEF greater than (\>) 35% between the 2 readings.
• Sinus rhythm or permanent, persistent, or paroxysmal atrial fibrillation flutter (AFF) (AFF at screening is capped at maximum 15% of participants enrolled) with mean resting heart rate of \>=55 and \<=90 beats per minute (bpm) at screening, and \>=50 and \<=95 bpm at randomization, regardless of rhythm.
• NT-proBNP \>=400 picograms per milliliter (pg/mL) in sinus rhythm and \>=800 pg/mL in AFF at screening (confirmed by central laboratory).
• Transvenous implantable cardioverter-defibrillator (ICD) for primary prevention with back-up pacing set at 40 bpm.
• Treated with optimal, stable, medical therapy for HF consistent with prevailing local and international guidelines unless contraindicated or not tolerated, as judged and documented by the investigator.

You may not qualify if:

• Any acute or serious co-morbid condition that could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
• Admitted to hospital with the primary reason of HF within 24 hours before randomization or currently hospitalized with the primary reason of HF for more than 10 days. Current hospitalization (\>24 hours and \<=10 days) is capped at a maximum of 15% of participants enrolled.
• Acute coronary syndrome, stroke or transient ischemic attack, severe ventricular arrhythmia, or major cardiac intervention, percutaneous coronary intervention, valvuloplasty/other cardiac valve repair or implantation, or cardiac surgery within 60 days before randomization.
• Systolic blood pressure \>130 or ˂90 millimeters of mercury (mmHg) at screening, or \>140 or ˂85 mmHg at randomization.
• Uncontrolled diabetes mellitus, defined as Hemoglobin A1c (HbA1c) \>=9.0% (\>=75 millimoles per mole \[mmol/mol\]) at screening, or severe complications of diabetes.
• Body weight \<50 kilogram (kg) or body mass index (BMI) \<18 kilograms per square meter (kg/m\^2) or \>45 kg/m\^2 at screening.
• Any of the following electrocardiogram (ECG) findings at screening: Corrected QT interval using Fridericia's formula (QTcF) \>450 milliseconds (ms), 1st degree atrioventricular (AV) block with PQ \>240 ms, or AV block 2nd or 3rd degree.
• History of aborted cardiac arrest, sustained ventricular tachycardia, or Torsades-de Pointes, or congenital long QT syndrome. Family history of sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia.
• Cardiac resynchronization therapy, Cardiac Contractility Modulation, or pacemaker device other than the back-up pacing function of the ICD.
• Mechanical hemodynamic support, kidney support, or ventilation within 7 days before randomization.
• Treatment with i.v. inotropes, i.v. vasodilators, or i.v. vasopressors within 3 days before randomization.
• Treatment with any i.v. diuretics or supplemental oxygen within 6 hours before randomization.
• Use of any drugs or substances known to be strong inducers of Cytochrome P450 3A4 (CYP3A4) enzyme within 28 days before randomization or planned to be used during the study period or strong inhibitors of CYP3A4 within 7 days before randomization or planned to be used during the study period.
• Use of any drug that is known to prolong the QT interval (for example, sotalol, dofetilide, macrolides, some antidepressants, and some antipsychotics) within 28 days before randomization or planned to be used during the study period.
• Treatment changes in glucose lowering therapy within 28 days before randomization.

Sponsors & Collaborators

• AnaCardio AB: lead

MeSH Terms

Conditions

Heart Diseases; Cardiovascular Diseases; Heart Failure

Central Study Contacts

Robert Edfors, MD, PhD

CONTACT

+46 760 542 609; studyinfo@anacardio.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 4, 2026
• First Posted: May 13, 2026
• Study Start (Estimated): August 15, 2026
• Primary Completion (Estimated): April 22, 2028
• Study Completion (Estimated): May 22, 2028
• Last Updated: May 13, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: Links to the Study Protocol and Statistical Analysis Plan will be made available on ClinicalTrials.gov